Why the study?
Two-thirds of diabetic patients may develop diabetic cardiomyopathy, a life-threatening condition for which no curative treatment currently exists.
Does a nano-caffeine emulsion improve myocardial injury and fibrosis in a rat model of diabetic cardiomyopathy?
Does a nano-caffeine emulsion improve myocardial injury and fibrosis in a rat model of diabetic cardiomyopathy?
A novel calcium carbonate-stabilized nano-caffeine emulsion significantly attenuated diabetic cardiomyopathy in rats by improving antioxidant, anti-inflammatory, and anti-fibrotic pathways compared to standard caffeine.
Hypothesis-generating for nano-caffeine in diabetic cardiomyopathy; extends caffeine's cardioprotective effects via enhanced delivery but should not yet change practice.
Rasha A Mansouri,1,2 Esam M Aboubakr,3 Huda F Alshaibi,2,4 Wafaa M Fouda,5 Abeer A Banjabi,2 Maha Mohammed Al-Bazi,2 Hamdoon A Mohammed,6 Adel M Ahmed7 1Chemistry Department, Faculty of Science and Humanities, Prince Sattam bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia; 2Biochemistry Department, Faculty of Sciences, King Abdulaziz University, Jeddah, 22254, Saudi Arabia; 3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Qena University, Qena, 83523, Egypt; 4Embryonic Stem Cell Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 22254, Saudi Arabia; 5Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Sadat City, Sadat, Egypt; 6Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah, Saudi Arabia; 7Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Qena University, Qena, 83523, EgyptCorrespondence: Adel M Ahmed, Email adelpharma2004@svu.edu.eg Hamdoon A Mohammed, Email ham.mohammed@qu.edu.saIntroduction: Type 2 diabetes mellitus (T2DM) is one of the most commonly diagnosed metabolic diseases. Notably, two-thirds of diabetic patients may develop diabetic cardiomyopathy (DCM), a life-threatening condition for which no curative treatment currently exists.Methods: This study aimed to investigate the potential ameliorative effects of caffeine against DCM development, utilizing a novel oral sustained-release caffeine-loaded Pickering emulsion formula stabilized by calcium carbonate nanoparticles to enhance its pharmaceutical and pharmacological properties. Eighty-four rats were divided into seven groups: control, caffeine, nano-caffeine, diabetic, diabetic + rosuvastatin, diabetic + caffeine, and diabetic + nano-caffeine.Results: Our findings demonstrated that the newly developed nano-caffeine formulation significantly downregulated myocardial injury markers (CK-MB, cTnI, ALT, AST, and LDH) and markedly ameliorated myocardial tissue injury and fibrosis, as confirmed by histopathological examination and desmin/α-SMA expression analysis. Additionally, the nano-caffeine treatment reduced inflammatory cytokines (TNF-α and IL-1β), attenuated hyperlipidemia, decreased iNOS and NO myocardial concentrations, and upregulated protective antioxidants (Nrf2, GSH, GSH-Px, SOD, and catalase) compared to the control group. Importantly, the cardioprotective effects of nano-caffeine were more pronounced than those observed in caffeine-treated diabetic rats. Furthermore, a novel, simple, and validated HPLC method was employed to quantify caffeine levels in cardiac tissues in all groups. The analysis revealed significantly higher caffeine concentrations in the nano-caffeine group compared to other groups, indicating improved tissue delivery.Conclusion: The formulation significantly enhances the cardioprotective effects of caffeine against myocardial injury in T2DM rats by optimizing its pharmacodynamic and pharmacokinetic properties.
No takes yet. Share an insight, caveat, or question.
Mansouri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: